Balaxi

Hyderabad, India Founded: 1942 • Age: 84 yrs Listed
Drug distribution and storage services are provided by Balaxi.

About Balaxi

Balaxi is a publicly listed company based in Hyderabad (India) founded in 1942 by Ashish Maheshwari. Drug distribution and storage services are provided by Balaxi. The company has 197 employees. Its Indian entity Balaxi Pharmaceuticals Limited reported revenue of ₹273 Cr. Balaxi offers products and services including Pharmaceutical Products and Branded Consumer Products. Its focus areas include Traditional Pharmaceuticals, Diversified, Conglomerates and Traditional Conglomerates.

Company details

Balaxi was established in 1942 in Hyderabad, India, by Ashish Maheshwari as founder and managing director. Operations are centered on the pharmaceutical sector, where drug distribution and storage services are managed. These activities support supply chain needs for medications, with a focus on reliable logistics and compliance in the Indian market. The companys domain, balaxipharma.in, facilitates online access to its offerings.

Key Metrics
  • Market Cap
    ₹146 Cr

    BALAXI · NSE

  • Share Price
    ₹31.65

    +19.57% today

  • Revenue
    ₹270 Cr

    FY 2025-26 · -7.7% YoY

  • EBITDA
    ₹8.52 Cr

    Margin 3.1%

  • Net Profit
    ₹1.42 Cr

    FY 2025-26 · -94.4% YoY

  • P/E (TTM)
    38.5x

    P/B 0.5x

  • ROE
    0.6%

    ROCE 3.5%

  • Debt / Equity
    0.23

    Interest cover 66.8x

  • Employee Count
    197

Products & Services of Balaxi

Balaxi offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Branded Consumer Products.

Pharmaceutical Products
Medicines

A portfolio of over 300 products across therapeutic areas is managed for distribution in frontier markets.

Branded Consumer Products
Oral Care

Products such as oral care items are distributed globally to serve consumer needs.

Board of directors of Balaxi Pharmaceuticals Limited (Balaxi)

Balaxi Pharmaceuticals Limited is the primary company behind Balaxi. The board of Balaxi Pharmaceuticals Limited currently have 6 directors; the longest-serving is Ashish Maheshwari, appointed in 2017. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ashish Maheshwari
DIN 01575984
Managing Director04 May 20179 yrs 6 moBalaxi Pharmaceuticals Limited
Minoshi Maheshwari
DIN 01575975
Director04 May 20179 yrs 6 moBalaxi Pharmaceuticals Limited
Kunal Mahendra Bhakta
DIN 01710557
Director04 May 20179 yrs 6 moBalaxi Pharmaceuticals Limited
Gandhi Gamji
DIN 01944694
Director04 May 20179 yrs 6 moBalaxi Pharmaceuticals Limited
Mangina Srinivas Rao
DIN 08095079
Director15 Sep 20206 yrs 2 moBalaxi Pharmaceuticals Limited
Akshita Surana
DIN 10026552
Director05 Sep 20242 yrs 2 moBalaxi Pharmaceuticals Limited

People of Balaxi

4 people are tracked at Balaxi (2 in leadership, 2 in team); the tracked headcount is 197.

NameRoleGroup
Founder & Managing DirectorLeadership
Paridhi Maheshwari
Vice President Of Business DevelopmentLeadership
Ram Chawla
Country ManagerTeam
Chirag Darji
Branch ManagerTeam
Premium access

Complete people profiles for Balaxi

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Balaxi

Balaxi is a publicly listed company on the NSE with ticker symbol BALAXI in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date03 Dec 2015
  • Listed onNSE: BALAXI
  • Listed entityBalaxi Pharmaceuticals Limited
  • Exchange sectorDistribution services
  • ISININE618N01022
  • Share price₹22.18 (-0.05% on the day) · 2026-10-14
  • Market capitalisation₹123 Cr
  • Price to earnings10.1
  • Volume (last session)8,605

Financials of Balaxi

Exchange-reported figures of Balaxi Pharmaceuticals Limited, the listed company behind Balaxi (NSE: BALAXI).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹270 Cr
-7.7% YoY
EBITDA
₹8.52 Cr
-73.6% YoY
Profit After Tax
₹1.42 Cr
-94.4% YoY
Net Worth
₹249 Cr
+7.5% YoY
Total Assets
₹307 Cr
+7.6% YoY
Total Debt
₹57.65 Cr
+7.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue27029324133627923145.63
Revenue growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
EBITDA8.5232.226.2357.4150.8142.678.25
EBITDA margin+3.2%+11.0%+2.6%+17.1%+18.2%+18.5%+18.1%
Profit before tax5.2928.681.9956.9254.5144.328.78
Net profit1.4225.16(49.85)45.9647.6538.136.09
Net profit margin+0.5%+8.6%-20.7%+13.7%+17.1%+16.5%+13.4%
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
Balance sheet
Total assets30728522119611768.6427.75
Net worth24923220118311364.9827.75
Total debt57.6553.4319.4013.303.643.660.00
Cash & bank14.5639.4062.2928.227.191.674.00
Net working capital22321917415181.3762.7426.62
Cash flow
Cash from operations(4.50)(35.00)4.876.0834.140.00(14.04)
Cash from investing(20.78)(21.76)(1.05)(10.57)(28.45)(5.97)(0.18)
Cash from financing0.4433.8830.2525.51(0.16)3.6518.10
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3780.6870.7172.5456.1870.7476.2773.29
Revenue growth (YoY)+44.8%+14.1%-7.3%-1.0%-27.4%+7.8%--
Other income(0.83)(0.99)2.920.101.59(1.78)(1.69)3.94
EBITDA5.124.660.123.091.174.1512.563.99
EBITDA margin+6.3%+5.8%+0.2%+4.3%+2.1%+5.9%+16.5%+5.4%
Depreciation1.420.850.650.560.480.460.460.48
Interest0.860.730.991.020.891.010.741.38
Profit before tax2.012.091.401.611.390.909.676.07
Tax0.870.800.791.301.160.611.020.71
Net profit1.141.290.610.310.230.298.655.36
EPS (₹)0.210.240.110.060.040.051.560.97
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue80.8560.9970.2010810186.8745.63
Revenue growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
EBITDA0.762.615.3516.8717.3019.028.65
EBITDA margin+0.9%+4.3%+7.6%+15.6%+17.1%+21.9%+19.0%
Profit before tax7.035.285.5822.4419.7020.599.18
Net profit5.153.603.6916.2114.6715.136.49
Net profit margin+6.4%+5.9%+5.3%+15.0%+14.5%+17.4%+14.2%
EPS (₹)0.930.650.6715.9314.6715.136.50
Balance sheet
Total assets16916013710559.8446.7528.11
Net worth13312812292.1157.9143.2528.11
Total debt35.2932.1815.7012.441.933.510.00
Cash & bank5.3328.6944.0617.880.840.483.57
Net working capital48.3110610774.9432.0426.5226.91
Cash flow
Cash from operations43.87(7.60)(1.83)(7.07)8.8913.46(14.37)
Cash from investing(67.77)(24.98)0.46(2.29)(6.87)(20.03)(0.28)
Cash from financing0.5417.2127.5526.39(1.64)3.4918.10
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue26.2915.5820.2424.5919.3116.719.6511.16
Revenue growth (YoY)+36.2%-6.8%+109.7%+120.3%-8.7%-12.2%--
Other income1.080.923.371.624.210.460.322.92
Total expenses25.9616.5822.1723.2118.5416.1710.3011.06
EBITDA0.33(1.00)(1.93)1.380.770.54(0.65)0.10
EBITDA margin+1.3%-6.4%-9.5%+5.6%+4.0%+3.2%-6.7%+0.9%
Depreciation0.590.590.310.150.120.110.110.11
Interest0.570.450.710.730.620.630.690.57
Profit before tax0.25(1.12)0.422.124.240.26(1.13)2.34
Tax0.140.140.260.590.970.060.040.59

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3780.6870.7172.5456.1870.7476.2773.29
Revenue growth (YoY)+44.8%+14.1%-7.3%-1.0%-27.4%+7.8%--
Other income(0.83)(0.99)2.920.101.59(1.78)(1.69)3.94
EBITDA5.124.660.123.091.174.1512.563.99
EBITDA margin+6.3%+5.8%+0.2%+4.3%+2.1%+5.9%+16.5%+5.4%
Depreciation1.420.850.650.560.480.460.460.48
Interest0.860.730.991.020.891.010.741.38
Profit before tax2.012.091.401.611.390.909.676.07
Tax0.870.800.791.301.160.611.020.71
Net profit1.141.290.610.310.230.298.655.36
EPS (₹)0.210.240.110.060.040.051.560.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue27029324133627923145.63
Revenue growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
Other income2.822.360.632.644.972.230.59
Total expenses26226023527922918937.38
Employee cost0.0034.7428.0428.9512.478.472.10
EBITDA8.5232.226.2357.4150.8142.678.25
EBITDA margin+3.2%+11.0%+2.6%+17.1%+18.2%+18.5%+18.1%
Depreciation2.151.892.101.750.510.300.01
Interest3.904.012.771.380.760.280.05
Profit before tax5.2928.681.9956.9254.5144.328.78
Tax3.873.604.4010.966.866.192.69
Net profit1.4225.16(49.85)45.9647.6538.136.09
Net profit margin+0.5%+8.6%-20.7%+13.7%+17.1%+16.5%+13.4%
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0411.0410.9010.1810.0010.0010.00
Reserves & surplus23822118716210354.9817.75
Shareholders' funds (net worth)24923220118311364.9827.75
Minority interest0.000.000.000.000.000.000.00
Secured loans1.300.000.000.070.130.150.00
Unsecured loans56.3553.4319.4013.233.513.510.00
Total debt57.6553.4319.4013.303.643.660.00
Total liabilities30728522119611768.6427.75
Assets
Gross block85.8142.8842.9843.0029.232.740.19
Net block81.6840.9940.8841.4028.762.440.19
Capital work in progress0.0022.072.312.830.570.000.00
Investments0.000.000.000.000.003.420.00
Inventories83.4878.4882.1710598.7013.620.83
Sundry debtors13611155.7152.2827.5676.7629.71
Cash & bank balances14.5639.4062.2928.227.191.674.00
Loans & advances17.2914.0910.017.997.551.720.31
Total current assets25124321019414193.7734.85
Total current liabilities28.7324.1536.5342.3959.6331.038.23
Net working capital22321917415181.3762.7426.62
Total assets30728522119611768.6427.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash39.4062.2928.217.191.663.980.10
Net cash from operating activities(4.50)(35.00)4.876.0834.140.00(14.04)
Net cash from investing activities(20.78)(21.76)(1.05)(10.57)(28.45)(5.97)(0.18)
Net cash from financing activities0.4433.8830.2525.51(0.16)3.6518.10
Net change in cash(24.84)(22.89)34.0721.025.53(2.32)3.88
Closing cash14.5639.4062.2928.227.191.674.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.7%+21.3%-28.3%+20.4%+20.8%+407.0%-
EBITDA growth-73.6%+417.2%-89.2%+13.0%+19.1%+417.2%-
PBT growth-81.6%+1340.7%-96.5%+4.4%+23.0%+404.8%+258.4%
Net income growth-94.4%+150.5%-208.5%-3.6%+25.0%+526.1%-
Revenue CAGR (3Y)-7.1%+1.6%+1.4%+94.6%+173.9%--
EBITDA CAGR (3Y)-45.0%-9.0%-47.3%+90.9%+219.4%--
Profitability & leverage
Net income margin+0.5%+8.6%-1.0%+13.7%+17.1%+16.5%+13.4%
Return on capital employed+3.5%+12.9%+20.7%+37.3%+59.6%+92.6%+56.5%
Return on net worth+0.6%+11.6%-25.9%+31.1%+53.5%+82.3%+39.0%
Debt / equity0.230.170.090.060.040.040.00
Long-term debt / equity0.100.060.010.010.000.000.00
Interest cover66.8511.0267.072.481.510.660.61
Efficiency & per share
Fixed asset turnover4.206.815.619.3217.48157.90456.30
Inventory turnover3.343.642.583.304.9732.02109.95
Debtors turnover2.193.514.478.435.364.352.59
EPS (₹)0.264.54(0.44)45.1447.6638.146.10
Dividend per share (₹)0.000.000.000.000.500.000.00
Book value per share (₹)45.1241.9836.26169.51113.1664.9827.75
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue26.2915.5820.2424.5919.3116.719.6511.16
Revenue growth (YoY)+36.2%-6.8%+109.7%+120.3%-8.7%-12.2%--
Other income1.080.923.371.624.210.460.322.92
Total expenses25.9616.5822.1723.2118.5416.1710.3011.06
EBITDA0.33(1.00)(1.93)1.380.770.54(0.65)0.10
EBITDA margin+1.3%-6.4%-9.5%+5.6%+4.0%+3.2%-6.7%+0.9%
Depreciation0.590.590.310.150.120.110.110.11
Interest0.570.450.710.730.620.630.690.57
Profit before tax0.25(1.12)0.422.124.240.26(1.13)2.34
Tax0.140.140.260.590.970.060.040.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue80.8560.9970.2010810186.8745.63
Revenue growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
Other income9.675.372.406.602.751.810.59
Total expenses80.0958.3864.8591.2783.9967.8536.98
Employee cost0.004.875.044.042.901.951.75
EBITDA0.762.615.3516.8717.3019.028.65
EBITDA margin+0.9%+4.3%+7.6%+15.6%+17.1%+21.9%+19.0%
Depreciation0.700.460.510.520.250.090.01
Interest2.702.241.660.510.100.150.05
Profit before tax7.035.285.5822.4419.7020.599.18
Tax1.881.681.936.235.035.462.69
Net profit5.153.603.6916.2114.6715.136.49
Net profit margin+6.4%+5.9%+5.3%+15.0%+14.5%+17.4%+14.2%
EPS (₹)0.930.650.6715.9314.6715.136.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0411.0410.9010.1810.0010.0010.00
Reserves & surplus12211710771.6347.9133.2518.11
Shareholders' funds (net worth)13312812292.1157.9143.2528.11
Secured loans1.300.000.150.490.930.000.00
Unsecured loans33.9932.1815.5511.951.003.510.00
Total debt35.2932.1815.7012.441.933.510.00
Total liabilities16916013710559.8446.7528.11
Assets
Gross block42.077.137.618.412.450.780.19
Net block41.376.677.107.892.200.690.19
Capital work in progress0.0022.072.312.830.570.000.00
Investments79.5125.0719.8819.5419.6119.540.10
Inventories0.000.000.841.490.000.020.83
Sundry debtors64.2089.9276.7678.2952.1148.1331.22
Cash & bank balances5.3328.6944.0617.880.840.483.57
Loans & advances1.070.991.241.361.120.051.08
Total current assets70.6012012399.0254.0748.6836.70
Total current liabilities22.2913.3816.0824.0822.0322.169.79
Net working capital48.3110610774.9432.0426.5226.91
Total assets16916013710559.8446.7528.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash28.6844.0617.870.840.473.550.10
Net cash from operating activities43.87(7.60)(1.83)(7.07)8.8913.46(14.37)
Net cash from investing activities(67.77)(24.98)0.46(2.29)(6.87)(20.03)(0.28)
Net cash from financing activities0.5417.2127.5526.39(1.64)3.4918.10
Net change in cash(23.35)(15.37)26.1917.040.38(3.08)3.44
Closing cash5.3328.6944.0617.880.840.483.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.6%-13.1%-35.1%+6.8%+16.6%+90.4%-
EBITDA growth-70.9%-51.2%-68.3%-2.5%-9.0%+119.9%-
PBT growth+33.1%-5.4%-75.1%+13.9%-4.3%+124.3%+274.7%
Net income growth+43.1%-2.4%-77.2%+10.5%-3.0%+133.1%-
Revenue CAGR (3Y)-9.2%-15.6%-6.9%+33.3%+95.3%--
EBITDA CAGR (3Y)-61.1%-46.8%-34.5%+24.9%+123.0%--
Profitability & leverage
Net income margin+6.4%+5.9%+5.2%+15.0%+14.5%+17.4%+14.2%
Return on capital employed+6.1%+5.1%+6.0%+27.9%+37.2%+55.4%+58.4%
Return on net worth+4.0%+2.9%+3.4%+21.6%+29.0%+42.4%+41.1%
Debt / equity0.260.190.130.100.050.050.00
Long-term debt / equity0.010.010.020.010.000.000.00
Interest cover1,010.34104.1934.303.120.590.790.58
Efficiency & per share
Fixed asset turnover3.298.288.7619.9262.72179.11456.30
Inventory turnover0.00145.2160.26145.1510,129.00204.40109.95
Debtors turnover1.050.730.911.662.022.192.49
EPS (₹)0.930.650.6715.9314.6715.136.50
Dividend per share (₹)0.000.000.000.000.500.000.00
Book value per share (₹)24.0923.1621.6180.3557.9143.2528.11

Web traffic of Balaxi

The website of Balaxi (balaxipharma.in) receives about 1.9K visits a month.

  • Monthly visits
    1.9K

    ▼ 32.9% vs previous month

Similar websites

Websites whose visitors overlap most with Balaxi. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
sudarshanpharma.com
100%
4.4K#2,511,746View details
innovacaptab.com
85%
2.7K#6,046,003View details

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Balaxi (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Balaxi

Premium access

Complete news archive for Balaxi

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Balaxi

Balaxi was founded in 1942.

Balaxi is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Balaxi has 197 employees.

The primary company behind Balaxi, Balaxi Pharmaceuticals Limited, reported revenue of ₹273 Cr for FY 2026, down 8% year on year.

Balaxi was established in 1942 in Hyderabad, India, by Ashish Maheshwari as founder and managing director. Operations are centered on the pharmaceutical sector, where drug distribution and storage services are managed. These activities support supply chain needs for medications, with a focus on reliable logistics and compliance in the Indian market. The companys domain, balaxipharma.in, facilitates online access to its offerings.

Balaxi offers Pharmaceutical Products and Branded Consumer Products.

Yes, Balaxi is publicly traded on NSE under the ticker symbol BALAXI.

Balaxi operates through Balaxi Pharmaceuticals Limited.

The legal entities of Balaxi currently have 8 directors, including Ashish Maheshwari, Mangina Srinivas Rao, Amol Anand Mantri and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available